Companies Kodiak Sciences Inc.
Kodiak Sciences (KOD): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Kodiak Sciences Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers27th pct.Of 15 peer CEOs
CEO pay, last three years
- $2,725,068FY2023
- $1,988,095FY2024
- $2,499,221FY2025
CEO total pay was $2,499,221 in fiscal 2025, up from $1,988,095 in fiscal 2024.
FY2025: salary $792,497 · bonus $0 · stock awards $0 · option awards $923,032
Executives and directors
Victor Perlroth · CEOJohn Borgeson · CFOBassil I. Dahiyat, Ph.D · Independent DirectorCharles A. Bancroft · Independent DirectorFelix J. Baker, Ph.D · Independent DirectorRichard S. Levy, M.D · Independent DirectorRobert A. Profusek, J.D · Lead Independent DirectorTaiyin Yang, Ph.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Kodiak Sciences Inc. in fiscal 2025?
As disclosed, Victor Perlroth (Chief Executive Officer and Chairman of the Board) was the highest-paid executive at Kodiak Sciences Inc. in fiscal 2025, with total compensation of $2,499,221.
How does Kodiak Sciences Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Victor Perlroth's total compensation ranked at the 27th percentile of Kodiak Sciences Inc.'s disclosed peer group.
How did shareholders vote on Kodiak Sciences Inc.'s executive compensation?
As disclosed, 99.35% of shareholders supported Kodiak Sciences Inc.'s executive compensation in the latest say-on-pay vote.
How much does Kodiak Sciences Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Kodiak Sciences Inc. reported total board compensation of $324,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Victor Perlroth | $792,497 | $0 | $0 | $923,032 | $772,824 | $0 | $10,868 | $2,499,221 |
| Chief Executive Officer and Chairman of the Board | ||||||||
| John Borgeson | 552,968 | 0 | 0 | 678,700 | 373,321 | 0 | 10,868 | 1,615,857 |
| Executive Vice President, Chief Financial Officer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Victor Perlroth | $2,499,221 | $1,988,095 | $2,725,068 | ↑ +511,126 |
| John Borgeson | 1,615,857 | 1,355,719 | 1,679,701 | ↑ +260,138 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company aims to attract, retain, and motivate superior executive talent by providing incentives that reward the achievement of performance goals correlating to stockholder value. A substantial portion of compensation is variable and at-risk, tied directly to measurable performance, with a strong emphasis on long-term equity incentives to align executive interests with stockholders.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Victor Perlroth | OPTION | — | — | — | — | — | $923,032 |
| John Borgeson | OPTION | — | — | — | — | — | 678,700 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Victor Perlroth | $0 | $0 | $923,032 | 0.0% |
| John Borgeson | 0 | 0 | 678,700 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| John Borgeson | Option | 20,782 | 8.15 | — |
| Victor Perlroth | Option | 47,396 | 8.15 | — |
| John Borgeson | Option | 82,136 | 7.24 | — |
| Victor Perlroth | Option | 132,605 | 7.24 | — |
| John Borgeson | Option | 216,032 | 2.49 | — |
| John Borgeson | Option | 223,959 | 3.95 | — |
| Victor Perlroth | Option | 262,209 | 2.49 | — |
| John Borgeson | Option | 500,000 | 88.21 | — |
| Victor Perlroth | Option | 2,177,334 | 88.21 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Robert A. Profusek, J.DIndependent · Compensation · Nominating and Governance (Chair) | $86,500 | $0 | $92,800 | $0 | $0 | $179,300 |
| Charles A. BancroftIndependent · Audit (Chair) · Compensation · Nominating and Governance | 77,500 | 0 | 92,800 | 0 | 0 | 170,300 |
| Taiyin Yang, Ph.DIndependent · Audit · Partial-year service | 55,000 | 0 | 92,800 | 0 | 0 | 147,800 |
| Bassil I. Dahiyat, Ph.DIndependent · Audit · Partial-year service | 55,000 | 0 | 92,800 | 0 | 0 | 147,800 |
| Richard S. Levy, M.DIndependent · Nominating and Governance | 50,000 | 0 | 92,800 | 0 | 0 | 142,800 |
| Felix J. Baker, Ph.DIndependent · Compensation (Chair) · Nominating and Governance · Partial-year service | 0 | 0 | 92,800 | 0 | 0 | 92,800 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $324,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $324,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Kodiak Sciences as a peer
Companies that benchmark against KOD
7 companies name KOD as a compensation peer
The list of companies that name KOD as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
FDMT 4D Molecular TherapeuticsMRSN Mersana TherapeuticsABCL AbCellera BiologicsNKTR Nektar TherapeuticsALLO Allogene TherapeuticsOCGN OcugenANNX AnnexonCHRS Coherus BioSciencesVRDN Viridian TherapeuticsPRLD Prelude TherapeuticsEYPT EyePoint PharmaceuticalsRAPT RAPT TherapeuticsFATE Fate TherapeuticsHRTX Heron TherapeuticsMGTX MeiraGTx Holdings plc
Peer reciprocity
The companies Kodiak Sciences Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | MeiraGTx Holdings plc | 2025 | Alexandria Forbes | $840,000 | $5,823,500 | — | — | $8,330,006 |
| 2 | Rapt Therapeutics | 2024 | Brian Wong | 630,000 | 0 | 5,927,297 | 416,000 | 6,979,539 |
| 3 | Viridian Therapeutics | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 4 | AbCellera Biologics | 2025 | Carl Hansen | 550,000 | 0 | 5,361,934 | 0 | 6,293,085 |
| 5 | Nektar Therapeutics | 2025 | Howard Robin | 1,106,282 | 942,081 | 2,986,535 | 1,106,282 | 6,256,954 |
| 6 | Allogene Therapeutics | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 7 | EyePoint Pharmaceuticals | 2025 | Jay Duker | 696,251 | 1,610,700 | 2,604,113 | 632,700 | 5,568,352 |
| 8 | Ocugen | 2025 | Shankar Musunuri | 757,900 | 2,194,445 | 1,385,871 | 0 | 4,841,822 |
| 9 | Annexon | 2025 | Douglas Love | 670,833 | 0 | 2,522,260 | 371,250 | 3,579,202 |
| 10 | Heron Therapeutics | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 11 | Coherus BioSciences | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 12 | Kodiak Sciences Inc. | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 13 | Fate Therapeutics | 2025 | Bahram Valamehr | 600,000 | 0 | 1,283,868 | 360,000 | 2,248,568 |
| 14 | 4D Molecular Therapeutics | 2025 | David Kirn | 667,252 | 0 | 822,750 | 560,597 | 2,051,343 |
| 15 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 16 | Prelude Therapeutics | 2025 | Krishna Vaddi | 615,441 | 0 | 412,744 | 309,465 | 1,348,000 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Kodiak Sciences Inc. | 150% | not disclosed | not disclosed | Compensia, Inc. |
| 4D Molecular Therapeutics | 140% | Options 100 | not disclosed | Radford (part of the Rewards Solutions practice at Aon plc) |
| AbCellera Biologics | not disclosed | Option 100 | not disclosed | Alpine Rewards |
| Allogene Therapeutics | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Annexon | 100% of target% | not disclosed | not disclosed | Alpine Rewards |
| Coherus BioSciences | not disclosed | Option 100 | not disclosed | Aon |
| EyePoint Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| Fate Therapeutics | 100% | Options 100 | No | Aon's Human Capital Solutions practice (Radford) |
| Heron Therapeutics | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| MeiraGTx Holdings plc | not disclosed | RSU 100 | not disclosed | Total Compensation Solutions |
| Mersana Therapeutics | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Nektar Therapeutics | 100% | not disclosed | No | Aon |
| Ocugen | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners LLC |
| Prelude Therapeutics | not disclosed | Option 100 | not disclosed | Compensia |
| Rapt Therapeutics | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Viridian Therapeutics | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-02 | 49,157,143 | 323,196 | 21,005 | 99.35% | Passed |
| 2025 | 2025-06-02 | 35,200,864 | 2,365,796 | 49,473 | 93.7% | Passed |
| 2024 | 2024-06-04 | 36,430,878 | 4,405,093 | 39,312 | 89.21% | Passed |
| 2023 | 2023-06-06 | 32,457,916 | 5,299,673 | 43,642 | 85.96% | Passed |
| 2022 | 2022-06-07 | 32,519,426 | 3,748,425 | 31,564 | 89.66% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-02 | 99.35%a |
| 2025 | 2025-06-02 | 93.7%b |
| 2024 | 2024-06-04 | 89.21%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John Borgeson | Chief Financial Officer | 2026-06-04 | D | 30,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-06-04 | D | 4,104 | 35 | 142,286 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-06-04 | A | 30,000 | 1 | 31,200 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-06-04 | D | 25,896 | 34 | 880,723 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-30 | A | 17,731 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-30 | A | 17,731 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles A. Bancroft | Director | 2026-06-30 | A | 17,731 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Profusek | Director | 2026-06-30 | A | 17,731 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard S. Levy | Director | 2026-06-30 | A | 17,731 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Taiyin Yang | Director | 2026-06-30 | A | 17,731 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bassil I. Dahiyat | Director | 2026-06-30 | A | 17,731 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-07-15 | A | 66,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Victor Perlroth | Director | 2026-07-15 | A | 100,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Victor Perlroth | Director | 2026-09-25 | D | 314,684 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Victor Perlroth | Director | 2026-09-25 | D | 365,840 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Victor Perlroth | Director | 2026-09-25 | D | 600,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Victor Perlroth | Director | 2026-09-25 | A | 314,684 | 4 | 1,243,002 | Common | Form 4 ↗ |
| Victor Perlroth | Director | 2026-09-25 | A | 365,840 | 2 | 910,942 | Common | Form 4 ↗ |
| Victor Perlroth | Director | 2026-09-25 | A | 600,000 | 5 | 3,228,000 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 196,608 | 90 | 17,666,310 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 11,729 | 90 | 1,053,915 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 82,673 | 90 | 7,407,798 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 4,932 | 90 | 441,925 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 107,772 | 89 | 9,553,557 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 6,428 | 89 | 569,816 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 98,561 | 89 | 8,729,262 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 5,880 | 89 | 520,775 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 75,176 | 88 | 6,578,389 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 4,485 | 88 | 392,467 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 63,539 | 87 | 5,524,214 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 3,790 | 87 | 329,511 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 16,036 | 87 | 1,392,153 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 957 | 87 | 83,081 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 3,114 | 87 | 270,051 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 186 | 87 | 16,130 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 38,932 | 86 | 3,346,813 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 2,322 | 86 | 199,612 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 109,842 | 85 | 9,320,566 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 6,553 | 85 | 556,050 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 123,888 | 84 | 10,400,546 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 7,390 | 84 | 620,399 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 19,554 | 83 | 1,626,017 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 1,699 | 83 | 140,477 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 101 | 83 | 8,351 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 651 | 82 | 53,327 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 39 | 82 | 3,195 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 28,028 | 82 | 2,293,144 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 1,672 | 82 | 136,797 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 17,490 | 81 | 1,422,180 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 1,044 | 81 | 84,892 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 5,654 | 81 | 459,116 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 338 | 81 | 27,446 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 17,159 | 81 | 1,390,229 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 1,024 | 81 | 82,965 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 1,027 | 81 | 82,694 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 61 | 81 | 4,912 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 6,783 | 80 | 544,172 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 404 | 80 | 32,411 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 14,827 | 80 | 1,181,825 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 884 | 80 | 70,462 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 283 | 80 | 22,535 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 17 | 80 | 1,354 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 8,956 | 79 | 711,147 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 534 | 79 | 42,402 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 49,771 | 79 | 3,910,413 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 2,969 | 79 | 233,269 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 48,350 | 77 | 3,743,808 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 2,884 | 77 | 223,312 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 61,700 | 76 | 4,710,487 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 3,681 | 76 | 281,026 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 32,261 | 76 | 2,436,193 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 1,924 | 76 | 145,291 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 76,723 | 74 | 5,675,093 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 4,577 | 74 | 338,554 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 78,726 | 73 | 5,753,115 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 4,696 | 73 | 343,173 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 278,978 | 72 | 20,194,464 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 16,641 | 72 | 1,204,597 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 17,698 | 71 | 1,265,129 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 1,056 | 71 | 75,487 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 39,066 | 69 | 2,693,905 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 2,331 | 69 | 160,741 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 2,585 | 68 | 176,746 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 154 | 68 | 10,530 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 5,382 | 67 | 361,114 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 321 | 67 | 21,538 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 8,021 | 64 | 516,774 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 479 | 64 | 30,861 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 4,067 | 63 | 256,068 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 243 | 63 | 15,300 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 44,690 | 62 | 2,754,030 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 2,666 | 62 | 164,293 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 14,344 | 61 | 878,002 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 856 | 61 | 52,396 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-28 | A | 1,167 | 83 | 97,042 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-29 | A | 1,416 | 86 | 121,614 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-29 | A | 84 | 86 | 7,214 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-29 | A | 20,031 | 85 | 1,710,707 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-29 | A | 1,195 | 85 | 102,057 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-29 | A | 10,381 | 84 | 874,517 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-29 | A | 619 | 84 | 52,146 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-10-21 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-10-21 | D | 100 | 95 | 9,491 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-10-21 | D | 2,000 | 94 | 187,420 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-10-21 | D | 2,000 | 93 | 185,320 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-10-21 | D | 2,985 | 92 | 273,904 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-10-21 | D | 5,101 | 91 | 464,089 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-10-21 | D | 7,623 | 90 | 684,088 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-10-21 | D | 1,677 | 89 | 149,588 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-10-21 | D | 8,514 | 88 | 746,422 | Common | Form 4 ↗ |
| John Borgeson | Chief Financial Officer | 2026-10-21 | A | 30,000 | 2 | 74,700 | Common | Form 4 ↗ |
| Taiyin Yang | Director | 2026-10-23 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Taiyin Yang | Director | 2026-10-23 | A | 20,000 | 2 | 47,000 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (148 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Victor Perlroth. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table” · page 29. As printed: 2,499,221. View filing ↗
- Section 01, John Borgeson. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table”. As printed: 1,615,857. View filing ↗
- Section 03, Victor Perlroth OPTION. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, John Borgeson OPTION. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-31. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Robert A. Profusek, J.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 179,300. View filing ↗
- Section 08, Charles A. Bancroft. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 170,300. View filing ↗
- Section 08, Taiyin Yang, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 147,800. View filing ↗
- Section 08, Bassil I. Dahiyat, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 147,800. View filing ↗
- Section 08, Richard S. Levy, M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 142,800. View filing ↗
- Section 08, Felix J. Baker, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 92,800. View filing ↗
- Section 02, John Borgeson 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles A. Bancroft 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Profusek 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard S. Levy 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Taiyin Yang 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bassil I. Dahiyat 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victor Perlroth 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victor Perlroth 2026-09-25. Form 4, filed 2026-09-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victor Perlroth 2026-09-25. Form 4, filed 2026-09-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victor Perlroth 2026-09-25. Form 4, filed 2026-09-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victor Perlroth 2026-09-25. Form 4, filed 2026-09-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victor Perlroth 2026-09-25. Form 4, filed 2026-09-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victor Perlroth 2026-09-25. Form 4, filed 2026-09-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-29. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-29. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-29. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-29. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-29. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-29. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Borgeson 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Taiyin Yang 2026-10-23. Form 4, filed 2026-10-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Taiyin Yang 2026-10-23. Form 4, filed 2026-10-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-04. Item 5.07 · say-on-pay result. As reported: 99.35% (votes for as printed: 49,157,143). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-03. Item 5.07 · say-on-pay result. As reported: 93.7% (votes for as printed: 35,200,864). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-06. Item 5.07 · say-on-pay result. As reported: 89.21% (votes for as printed: 36,430,878). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 324,000 + equity 0 + all other 0 = 324,000, summed across the director compensation table rows.
- MeiraGTx Holdings plc, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in MeiraGTx Holdings plc's own proxy. As printed: 8,330,006. View filing ↗
- Rapt Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-14. CEO total compensation as printed in Rapt Therapeutics's own proxy. As printed: 6,979,539. View filing ↗
- Viridian Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Viridian Therapeutics's own proxy. As printed: 6,776,249. View filing ↗
- AbCellera Biologics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in AbCellera Biologics's own proxy. As printed: 6,293,085. View filing ↗
- Nektar Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Nektar Therapeutics's own proxy. As printed: 6,256,954. View filing ↗
- Allogene Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. View filing ↗
- EyePoint Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in EyePoint Pharmaceuticals's own proxy. As printed: 5,568,352. View filing ↗
- Ocugen, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ocugen's own proxy. As printed: 4,841,822. View filing ↗
- Annexon, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Annexon's own proxy. As printed: 3,579,202. View filing ↗
- Heron Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics's own proxy. As printed: 3,516,291. View filing ↗
- Coherus BioSciences, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus BioSciences's own proxy. As printed: 2,736,874. View filing ↗
- Kodiak Sciences Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Kodiak Sciences Inc.'s own proxy. As printed: 2,499,221. View filing ↗
- Fate Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Fate Therapeutics's own proxy. As printed: 2,248,568. View filing ↗
- 4D Molecular Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in 4D Molecular Therapeutics's own proxy. As printed: 2,051,343. View filing ↗
- Mersana Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. View filing ↗
- Prelude Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Prelude Therapeutics's own proxy. As printed: 1,348,000. View filing ↗
- Section 10a, Nektar Therapeutics reciprocity. DEF 14A. Nektar Therapeutics names Kodiak Sciences Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Ocugen reciprocity. DEF 14A. Ocugen names Kodiak Sciences Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗